Target intelligence / Profile preview

Hydroxyapatite crystal matrix (HA or HAp)

Target
HA or HAp
Molecular classification
Other (mineral matrix), Calcium phosphate mineral, Not a protein/biological macromolecule
01

Overview

Hydroxyapatite crystal matrix is the principal inorganic component of bones and teeth, conferring rigidity and structural strength. Its chemical composition is calcium phosphate, Ca₁₀(PO₄)₆(OH)₂, forming nanoscale plate or needle-like crystals, frequently organized along type I collagen fibers. This matrix provides mechanical support and acts as a calcium and phosphate reservoir. Hydroxyapatite in bone is often defective or carbonated, differing from synthetic, stoichiometric hydroxyapatite. In bone regeneration therapies, synthetic or natural hydroxyapatite is used as a scaffold to promote new bone growth. Pathologically, hydroxyapatite crystals can accumulate in certain diseases, such as calcific tendonitis or tumors. While the hydroxyapatite matrix itself is not a therapeutic target, it is critical in understanding bone physiology, pathology, and therapeutic interventions.

Other names
Hydroxyapatite matrixBone mineralApatitic bone mineralCarbonated hydroxyapatite
02

Mechanism of action

Adsorption to crystal surface (bisphosphonates attach to hydroxyapatite, preventing osteoclast-mediated dissolution); Incorporation as scaffold/material in bone regeneration therapies

03

Biological functions

Structural supportCalcium and phosphate storageBone strength and rigidityBone regeneration scaffold
04

Disease associations

OsteoporosisBone fracturesCalcification disorders (e.g., vascular calcification, breast tumor calcification)Dental pathologies (caries, enamel defects)
05

Safety considerations

Ectopic calcification (undesired hydroxyapatite deposition in soft tissues)Interference with bone growth/remodeling (if altered by disease or drugs)Possible immunogenicity or integration challenges for synthetic hydroxyapatite implants
06

Interacting drugs

Bisphosphonates

2 more in the full profile.

07

Biomarkers

Bone mineral density (BMD) measured by DEXA scan (clinic biomarker for osteoporosis)X-ray findings of hydroxyapatite deposits in soft tissue or tumors

Beyond the preview

Go deeper on Hydroxyapatite crystal matrix (HA or HAp).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxyapatite crystal matrix (HA or HAp).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call